fbpx

List – 29 Drug Patents that are Expiring in 2030

With the huge growth in the generic drug market, there is no doubt that generic companies (hey there!) are searching for drugs with a soon-to-be-expired label.

With a new week comes a new list of drug patents expiring. As always, the list includes not just the drug names but also other information like treatment, ingredients, and the disease they cure, which could help them (you) easily choose the drug most profitable to develop a generic version.

Without any delay, here is the list of drugs. Thank us later!

The article has a list of drug patents in 2030. You can get the drug patents expiration list from 2026 to 2030 in a PDF by filling out the form below.


Drug Patents Expiring in 2030

Tafinlar
Dabrafenib

More information about this Drug

Patents Expiration Date
US7994185 January 20, 2030
US8415345 January 20, 2030
US8703781 October 15, 2030

Dosage: Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: DABRAFENIB MESYLATE
Treatment: Braf (v600)-mutated Metastatic Melanoma

Copiktra
Duvelisib

More information about this Drug

Patents Expiration Date
US8193182 February 13, 2030
USRE46621 May 17, 2032

Dosage: Oral
Company: Secura Bio Inc
Ingredients: DUVELISIB
Treatment: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Follicular Lymphoma

Seglentis
Celecoxib/Tramadol

More information about this Drug

Patents Expiration Date
US10238668 April 19, 2030
US9012440 April 19, 2030
US8598152 April 19, 2030
US10245276 April 19, 2030

Dosage: Oral
Company: Kowa Pharmaceuticals America Inc
Ingredients: CELECOXIB; TRAMADOL HYDROCHLORIDE
Treatment: Management And Treatment Of Pain

Veltassa
Patiromer

More information about this Drug

Patents Expiration Date
US8337824 May 29, 2030

Dosage: Oral
Company: Vifor Pharma Inc
Ingredients: PATIROMER SORBITEX CALCIUM
Treatment: High Blood Potassium

Olumiant
Baricitinib

More information about this Drug

Patents Expiration Date
US8158616 June 8, 2030

Dosage: Oral
Company: Eli Lilly And Co
Ingredients: BARICITINIB
Treatment: Rheumatoid Arthritis And Covid-19

Voxzogo
Vosoritide

More information about this Drug

Patents Expiration Date
US8198242 June 11, 2030

Dosage: Subcutaneous
Company: Biomarin Pharmaceutical Inc
Ingredients: VOSORITIDE
Treatment: Achondroplasia

Apadaz
Acetaminophen/Benzhydrocodone

More information about this Drug

Patents Expiration Date
US9132125 July 1, 2030
US9549923 July 1, 2030
US8748413 July 10, 2030
US8461137 February 22, 2031

Dosage: Subcutaneous
Company: Kvk Tech Inc
Ingredients: ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE
Treatment: Moderate To Severe Pain

Segluromet
Ertugliflozin-Metformin

More information about this Drug

Patents Expiration Date
US8080580 July 13, 2030

Dosage: Subcutaneous
Company: Merck Sharp And Dohme Corp
Ingredients: ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE
Treatment: Type 2 Diabetes

Qinlock
Ripretinib

More information about this Drug

Patents Expiration Date
US8188113 July 27, 2030
US8461179 June 7, 2032

Dosage: Oral
Company: Deciphera Pharmaceuticals Llc
Ingredients: RIPRETINIB
Treatment: Advanced Gastrointestinal Stromal Tumor

Parsabiv
Etelcalcetide

More information about this Drug

Patents Expiration Date
US9701712 July 29, 2030
US9278995 July 29, 2030
US8377880 July 29, 2030
US8999932 February 7, 2031

Dosage: Intravenous
Company: Kai Pharmaceuticals Inc
Ingredients: ETELCALCETIDE
Treatment: Secondary Hyperparathyroidism

Alunbrig
Brigatinib

More information about this Drug

Patents Expiration Date
US9012462 July 31, 2030
US10385078 November 10, 2035

Dosage: Oral
Company: Takeda Pharmaceuticals USA Inc
Ingredients: BRIGATINIB
Treatment: Non Small Cell Lung Cancer

Brexafemme
Ibrexafungerp

More information about this Drug

Patents Expiration Date
US8188085 August 28, 2030
US10174074 January 19, 2035
US10927142 January 19, 2035

Dosage: Oral
Company: Scynexis Inc
Ingredients: IBREXAFUNGERP CITRATE
Treatment: Vulvovaginal Candidiasis (VVC)

Nubeqa
Darolutamide

More information about this Drug

Patents Expiration Date
US8975254 October 27, 2030
US9657003 October 27, 2030
US11046713 October 27, 2030
US10711013 October 27, 2030
US10383853 January 28, 2036
US10010530 January 28, 2036
US11168058 February 27, 2038

Dosage: Oral
Company: Bayer Healthcare Pharmaceuticals Inc
Ingredients: DAROLUTAMIDE
Treatment: Non-metastatic Castration-resistant Prostate Cancer

Harvoni/Hepcinat-LP
Ledipasvir/Sofosbuvir

More information about this Drug

Patents Expiration Date
US8822430 November 12, 2030
US8088368 November 12, 2030
US10039779 July 30, 2034

Dosage: Oral
Company: Gilead Sciences Inc
Ingredients: LEDIPASVIR; SOFOSBUVIR
Treatment: Hepatitis C

Rinvoq
Upadacitinib

More information about this Drug

Patents Expiration Date
USRE47221 December 1, 2030
US8962629 January 15, 2031
US10981923 October 17, 2036
US9951080 October 17, 2036
US11186584 October 17, 2036

Dosage: Oral
Company: Abbvie Inc
Ingredients: UPADACITINIB
Treatment: Rheumatoid Arthritis and Psoriatic Arthritis

Nerlynx
Neratinib

More information about this Drug

Patents Expiration Date
US7399865 December 29, 2030

Dosage: Oral
Company: Puma Biotechnology Inc
Ingredients: NERATINIB MALEATE
Treatment: Breast Cancer

Leave a Comment

Become a part of GreyB’s insider list

Get our distilled learning delivered to you.

Get the Sample Report

Fill out the form and get the report.